期刊
JOURNAL OF INFECTIOUS DISEASES
卷 209, 期 5, 页码 781-788出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jit549
关键词
Group B Streptococcus; neonate; neonatal sepsis; meningitis; glycoconjugate vaccine; immunization; serocorrelate; protective immunity
资金
- National Institute of Allergy and Infectious Disease, National Institutes of Health [AI-75326, AI-25495, AI-23339]
Background. Further reduction in the group B streptococcal (GBS) disease burden in neonates in the United States awaits an additional prevention strategy, such as maternal immunization. Methods. We performed a prospective, multicenter, case-control study of 33 mothers delivering neonates with early onset GBS infection (cases), and 99 age- and ethnicity-matched mothers colonized with the same capsular polysaccharide (CPS) types delivering healthy neonates (controls). Relative risk and absolute risk were calculated for early onset disease associated with concentrations of type Ia, III, or V CPS-specific antibody in maternal serum. Results. For GBS types Ia and III, maternal CPS-specific antibody concentrations of >= 0.5 mu g/mL were associated with a relative risk of approximately 0.1 (95% confidence intervals [CIs], .01-.74 and 0-.72, respectively; P = .02 for each), corresponding to a 90% risk reduction (by logistic regression). For type V, the relative risk was 0.3 (95% CI, .01-3.1), corresponding to a 70% risk reduction. By Bayesian modeling, the risk of early onset disease would decrease by 70% if maternal CPS-specific antibody concentrations for these 3 GBS types were >= 1 mu g/mL. Conclusions. Maternal CPS-specific antibody serum concentrations of >= 1 mu g/mL at the time of delivery appear to protect most neonates from early onset GBS type Ia and III disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据